# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
These initiatives are expected to generate $3 million in annual savings and position the Company for continued financial strength.
Maxim Group analyst Allen Klee upgrades Marpai (NASDAQ:MRAI) from Hold to Buy and announces $6 price target.
Marpai (NASDAQ:MRAI) reported quarterly losses of $(0.65) per share. This is a 60.37 percent increase over losses of $(1.64) pe...
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...
Marpai, Inc. ("Marpai" or the "Company") (NASDAQ:MRAI), an independent national Third-Party Administration (TPA...